We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

164 hedge funds and large institutions have $1.13B invested in Intellia Therapeutics in 2020 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 58 increasing their positions, 32 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $5.7M | Put options by funds: $2.52M

126% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 19

98% more capital invested

Capital invested by funds: $569M → $1.13B (+$558M)

81% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 32

17% more funds holding

Funds holding: 140 → 164 (+24)

2.78% more ownership

Funds ownership: 92.06% → 94.85% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
164
Holders Change
+24
Holders Change %
+17.14%
% of All Funds
3.36%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
43
Increased
58
Reduced
32
Closed
19
Calls
$5.7M
Puts
$2.52M
Net Calls
+$3.18M
Net Calls Change
+$3.73M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$23M
2
BlackRock
BlackRock
New York
+$21.4M
3
AIM
ARK Investment Management
Florida
+$19.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$14.8M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.2M

Top Sellers

Rank Fund Capital Flow
1
NAMA
Nikko Asset Management Americas
New York
-$15.4M
2
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$15.2M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.59M
4
IC
Ikarian Capital
Texas
-$2.26M
5
O
OrbiMed
New York
-$2.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$3.92M +$232K +13,643 +8%
O
27
OrbiMed
New York
$2.88M -$2.12M -125,000 -48%
Millennium Management
28
Millennium Management
New York
$2.87M +$2.32M +136,425 New
Nomura Holdings
29
Nomura Holdings
Japan
$2.81M +$2.27M +133,700 New
BBA
30
Baker Bros. Advisors
New York
$2.7M – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$2.68M +$146K +8,580 +7%
Goldman Sachs
32
Goldman Sachs
New York
$2.64M +$557K +32,759 +35%
ROTUOC
33
Regents of the University of California
California
$2.34M – – –
Wells Fargo
34
Wells Fargo
California
$2.32M +$504K +29,648 +37%
MIM
35
Monashee Investment Management
Massachusetts
$2.31M +$1.87M +110,000 New
CS
36
Credit Suisse
Switzerland
$2.26M +$802K +47,181 +78%
PP
37
PDT Partners
New York
$2.15M -$16.3K -957 -0.9%
Swiss National Bank
38
Swiss National Bank
Switzerland
$2.14M +$613K +36,100 +55%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$1.93M +$274K +16,107 +21%
AIM
40
Aigen Investment Management
New York
$1.88M +$870K +51,221 +134%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$1.86M +$168K +9,900 +13%
Deutsche Bank
42
Deutsche Bank
Germany
$1.8M +$212K +12,460 +17%
UBS Group
43
UBS Group
Switzerland
$1.8M +$69.2K +4,071 +5%
PIM
44
Platinum Investment Management
Australia
$1.76M – – –
Federated Hermes
45
Federated Hermes
Pennsylvania
$1.61M +$1.3M +76,391 New
GIM
46
Granahan Investment Management
Massachusetts
$1.6M +$288K +16,963 +29%
RJFSA
47
Raymond James Financial Services Advisors
Florida
$1.54M +$1.06M +62,527 +578%
SCM
48
Shelton Capital Management
Colorado
$1.44M – – –
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$1.39M +$131K +7,693 +13%
EWM
50
Elmwood Wealth Management
California
$1.35M +$256K +15,066 +31%
1
2
3 4 5

NTLA Hedge Fund Activity: Q2 2020 in Review

164 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2020, worth a combined $1.13B — up 98% from $569M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new NTLA positions and 19 closed out — a net gain of 24 holders — while 58 added to existing stakes and 32 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $23M. The largest seller was Nikko Asset Management Americas, cutting an estimated $15.4M.

  • 164 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2020, up from 140 in Q1 2020.
  • Funds reported $1.13B of Intellia Therapeutics stock for Q2 2020, up 98% quarter-over-quarter.
  • 43 funds opened new Intellia Therapeutics positions in Q2 2020 and 19 closed out, a net change of +24 holders.
  • The largest Intellia Therapeutics buyer in Q2 2020 was T. Rowe Price Associates, an estimated $23M added.
  • The largest Intellia Therapeutics seller in Q2 2020 was Nikko Asset Management Americas, an estimated $15.4M sold.

Based on aggregated 13F filings for Q2 2020.